NCT06963294View on ClinicalTrials.gov

Ketamine and Dexmedetomidine for Delirium in Joint Arthroplasty

NANot yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 5, 2026

Primary Completion Date

June 15, 2026

Study Completion Date

July 15, 2026

Conditions
Postoperative DeliriumPostoperative Cognitive Dysfunction
Interventions
DRUG

Ketamine

Ketamine will be administered as an intravenous infusion at 0.1 mg/kg/hour during surgery

Trial Locations (1)

34250

Istinye Üniversity, Istanbul

All Listed Sponsors
lead

Istinye University

OTHER

NCT06963294 - Ketamine and Dexmedetomidine for Delirium in Joint Arthroplasty | Biotech Hunter | Biotech Hunter